Staar Surgical Co (STAA)
Staar Surgical Co (STAA) is a global provider of minimally invasive ophthalmic surgical products, specializing in designing, manufacturing, and marketing advanced implantable lenses and related instruments. The company focuses on solutions for refractive and cataract surgeries, aiming to improve visual outcomes for patients.
Company News
Halper Sadeh LLC is investigating the potential fairness of STAAR Surgical Company's sale to Alcon for $28.00 per share, examining whether the company's board adequately protected shareholder interests.
Alcon reported Q2 sales of $2.58 billion, missing estimates, and lowered its 2025 sales forecast to $10.3-$10.4 billion due to tariff impacts and soft market conditions. The company's stock dropped 8.58% following the announcement.
STAAR Surgical reported Q2 FY2025 earnings with revenue of $44.3 million, exceeding analyst expectations despite significant revenue decline in China. The company is focusing on international markets and restructuring operations to manage challenges.
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.